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Different anesthesia methods can variably influence excitotoxic lesion effects on the brain. The 
main purpose of this review is to identify potential differences in the toxicity to nervous system 
cells of two common inhalation anesthesia methods, isoflurane and sevoflurane, used in 
combination with an excitotoxic lesion procedure in rodents. The use of bioassays in animal  
models has provided the opportunity to examine the role of specific molecules and cellular 
interactions that underlie important aspects of neurotoxic effects relating to calcium homeostasis 
and apoptosis activation. Processes induced by MNDA antagonist drugs involve translocation of 
Bax protein to mitochondrial membranes, allowing extra-mitochondrial leakage of cytochrome 
c, followed by sequence of changes that ending in activation of CASP-3. The literature 
demonstrates that the use of these anesthetics in excitotoxic surgery increases 
neuroinflammation activity facilitating the effects of apoptosis and necrosis on nervous system 
cells, depending on the concentration and exposure duration of the anesthetic. These 
inflammatory responses are possibly mediated by high numbers of microglia and astrocytes and 
high levels of proinflammatory cytokines and caspase activation. 
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Introduction 
 
Studies in animal models, especially in rodents, during recent years have identified possible  
toxic effects on the brain of using general inhaled anesthesia [1, 2]. The majority of researches 
have shown the susceptibility of brain development processes in the neonatal rat to N-metil-D- 
aspartate receptor (NMDAR) and Gamma-Aminobutyric Acid A (GABAA) receptor antagonist, 
which can result in massive apoptosis or necrosis [3-9]. 
 
Excitotoxic lesions in rodents result in two principal types of cell death, primary and secondary 
(Fig. 1, Extrinsic and Intrinsic pathway). In the first type, excitotoxicity is direct and occurs 
when there is an overactivation of glutamate receptors. Without energy to maintain the ionic 
gradients, the resting potential of neurons collapses. The resulting depolarization produces a 
massive release of the excitatory neurotransmitter glutamate and a lack of energy which is 
difficult to recapture by specific transporters [10, 11]. Some of the most used chemical 
substances for primary excitotoxic lesions are N-metil-D-aspartate (NMDA) and kainic acid 
(KA), ibotenic, and quinolinic or 2, 3-Pyridine-Dicarboxylic (QUIN) acid [12-15]. In the second 
type of cell death, the lesion is indirect and happens either when metabolic processes produce an 
accumulation of oxygen radicals by oxidative stress or when changes induced by mitochondrial 
impairment promote inflammation of cells in the nervous system [16-19]. This reaction causes 
overactivation of microglia producing cytokines such as tumor necrosis factor- alpha (TNF-α), 
interleukin-6 (IL-6), and interleukin-1βeta (IL-1β) [20, 21]. Another possible explanation may 
be caspase activation in the cell, producing chromatin condensation and deoxyribonucleic acid 
(DNA) fragmentation. These can be key features of apoptotic cells, which are ultimately 
eliminated by phagocytes [22-25]. 
 
The main inhalant anesthetics used today in experimental processes with rodents are isoflurane 
and sevoflurane. These volatile anesthetics can have neurodevelopmental effects depending on 
concentration and exposure duration, affected cell plasticity, and neurocognitive performance 
[19, 26-28]. When exposure to these anesthetics has been in the period between postnatal day 
(PD) 7 and PD14 it has been associated with apoptosis processes, especially in hippocampal  
stem cells and dentate gyrus (DG) granule neurons [19, 27, 29, 30]. The immature rodent brain 
is most vulnerable to anesthesia-induced neurotoxicity, whether administered by inhalation or 
intraperitoneal (i.p) injection, in the intrauterine period and up until 2 to 3 weeks after birth [19, 
31, 32]. However, the toxicity effects of inhaled anesthetics are not well understood, especially 
in the nerve cells of juvenile and adult rodents. 
This review has as its main aim briefly to discuss the effects of the use of the inhaled 
anesthetics, isoflurane and sevoflurane, in combination with excitotoxic lesion procedures in 
rodents. First, we describe the molecular effects of substances most commonly used in the 
models of excitotoxic injuries in rodents. Second, we analyze the studies of inhalant anesthetics 
and their role in the protection against or the induction of cytotoxicity in the cells of the nervous 
system. 
 
1. Molecular mechanisms of the substances used in the models of excitotoxic lesions 
in rodents 
The choice and use of the excitotoxins in the lesion model play a role important in the 
experimental studies with rodents, especially in stroke, traumatic brain injury, spinal cord injury 
and neurodegenerative diseases of the central nervous system. We describe the main molecular 
effects of NMDA, KA and QUIN in the nerve cells. 
 
1.1 NMDA and NMDAR 
 
 
Molecular mechanisms underlying preconditioning (the brain has the ability to protect itself  
against ischemia when it stimulated by some anesthetics and other drugs), the are not 
completely elucidated, with the possible implication on different occasions of NMDAR, nitric 
oxide synthase, cytokines, and mitochondrial oxidative stress. Bioenergetic modulation and 
suppression of the innate immune system are two of the elements that have pivotal roles in such 
processes [33-36]. NMDA and other glutamatergic agents in particular may act as chemical 
preconditioning agents in hippocampal slices [37], in cultured cells [38] and in in vivo models 
of excitotoxicity [39]. Additionally, subtoxic doses of NMDA (e.g., 75 mg/kg, i.p.) yield 
preconditioning against chemically-induced seizure [39, 40] or traumatic brain injury in vivo 
[41]. This concept was extended to in vivo models of QUIN induced seizures [33, 39, 42].  
Other research confirms that NMDA preconditioning does not induce neuronal death per se, and 
its neuroprotective mechanisms remain to be fully elucidated [43] . 
 
Recent studies show that NMDAR dysfunction contributes to the neurotoxicity that underlies 
many neurodegenerative disorders [44-48]. Examples of NMDAR that have been used to model 
pathogenesis of neurocognitive disorders associated with human immunodeficiency virus (HIV) 
involves a combination of factors [49], evidence suggests that the HIV protein trans activator of 
transcription (Tat) plays a prominent role by altering the activity of NMDARs [49-52] and 
impairing cognitive function [53-55]. Tat potentiated NMDAR function via lipoprotein- 
receptor-related protein-dependent activation of Src kinase. Also, NMDAR function adapted 
after activation of the nitric oxide synthases (NOS), soluble guanylate cyclase (sGC), and 
protein kinase G (PKG) pathways [50]. Additional research determined that a ras homolog gene 
family member A (RhoA) / associated kinase (ROCK) dependent remodeling of the actin 
cytoskeleton was an obligatory step in NMDAR adaptation. This function may be a 
neuroprotective mechanism to prevent excessive NMDAR-mediated Ca
2+
 influx [56]. On the 
other hand, activation and inhibition of RhoA profoundly affected neuronal morphology, 
consistent with previous reports [57, 58] that neurons expressing dominant negative (DN)-RhoA 
exhibited increased dendritic branching, whereas cells expressing CA-RhoA displayed 
simplified dendritic structures with minimal branching and no noticeable dendritic spines [56]. 
 
It has been shown that ROCK is the primary downstream target of RhoA and is a 
serine/threonine kinase that modifies the cytoskeleton to regulate cell migration and 
proliferation [59, 60], and that activation of ROCK in neurons induces rundown of NMDAR 
currents via an actin-dependent mechanism [61]. Additional research found that inhibition of 
ROCK prevented adaptation of NMDAR function following Tat-induced potentiation. These 
data indicate that Tat-induced activation of ROCK reduces NMDAR function. Abnormal 
activation of ROCK is also observed in many models of neuronal disorders including 
Alzheimer’s disease, spinal cord injury, neuropathic pain, and excitotoxicity lesion  [62]. 
 
Moreover, it has been shown that Tat affects the cytoskeleton: it depolymerizes actin in 
endothelial cells [63] and produces a loss of F-actin puncta in hippocampal neurons in vitro 
[64]. The data indicate that Tat activates a RhoA/ROCK pathway leading to remodeling of the 
actin cytoskeleton resulting in reduced NMDA-evoked responses [50]. The same research also 
indicates that the observed effects of Tat on NMDAR function may result from both direct 
effects on neurons and indirect effects on glia. Indeed, Tat promotes the release of glutamate 
[65], inflammatory cytokines [66], chemokines [67], and reactive oxygen species [68], from glia 
and neurons [50]. These substances all influence NMDAR function. 
 
However, studies in which DN constructs were expressed selectively in neurons determined that 
potentiation of NMDAR function required activation of neuronal Src kinase, while adaptation 
required activation of a neuronal NO signaling pathway [50]. ROCK is a valuable drug target 
with neuroprotective and neuroregenerative potential. The ROCK inhibitor, fasudil, is a well- 
tolerated vasodilator that has been used clinically [69], and is neuroprotective in models of 
Alzheimer’s disease [70], amyotrophic lateral sclerosis [71], and Parkinson’s disease [72].  
1.2 KA and Kainate acid receptor (KAR) 
 
 
Is a glutamate analog that stimulates excitatory neurotransmitter release and induces ischemia- 
like neuronal degeneration. It has been used to define mechanisms involved in  
neurodegeneration and neuroprotection, and is a powerful neurotoxic agent [73] that stimulates 
excitatory neurotransmitter release [74]. Systemic KA injection induces neuronal degeneration 
in certain brain areas, including the piriform cortex, amygdaloid complex, hippocampus, and 
septum [74-78]. The nature of neuronal degeneration caused by systemic KA injection 
resembles some forms of ischemia [79]. The degree of KA-induced neuronal injury is 
influenced by temperature, anesthesia, and anticonvulsant drugs [80, 81]. 
 
In general, the intranasal (IN) anesthesia has been shown to provoke acute central cytotoxicity 
and neuronal damage, reflecting the penetration of the anesthetic into the brain [82]. KA may be 
used to trigger electrographic status epileptics (ES) and the associated sequel of pro- 
inflammatory changes [83]. The results in one study, had shown IN KA induced ES on brain 
inflammation, and microglia- astrocytic cell activation, and hippocampal neurodegeneration. 
[84]. Moreover, the same research found phenotypic microglial activation and astrogliosis, 
along with transcriptional modifications of inflammatory genes. Microgliosis was observed as 
early as 24 hours after IN KA-induced ES; the results showed that microglial M1 and M2 genes 
were dysregulated. M1 corresponds to a pro-inflammatory status, correlating to or facilitating 
neuronal damage. In contrast, the anti-inflammatory M2 phenotype may be beneficial following 
pathological events in the brain [84, 85]. Typical pro-inflammatory brain changes were 
observed in this model, supporting disease pathophysiology. A possibility for tailoring this 
model to drug testing or to study mechanisms of disease is offered [86, 87]. 
 
KAR subunits play roles in the brain that are quite distinct from those played by other members 
of the ionotropic glutamate receptor (iGluR) family, despite structural and functional 
commonalities. While α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors 
(AMPARs) and NMDARs mediate most basal excitatory synaptic transmission due to their 
position in postsynaptic densities, KARs seem to have more diverse functions that rely on a 
diversity of subcellular localization and signaling mechanisms. They thus play a unique role in 
regulating the activity of neural circuits and are distributed throughout the nervous system [88].  
 
Interestingly, KARs are not involved in short-term plasticity at Schaffer collateral synapses onto 
CA1 pyramidal cells [89], pointing to the target-specific localization of presynaptic KARs in 
given afferents, in contrast to the moderate facilitation observed for other interneurons [90]. 
Presynaptic calcium-permeable KARs is thought to be involved in the short-term facilitation of 
glutamate release based on the use of the calcium-permeable receptor antagonist 1- napthyl 
acetyl spermine (NASPM) [90]. Excitatory synapses, in cells of the striatum orients, also show 
pronounced facilitation, which is attenuated with NS102, a selective glutamate receptor 
ionotropic kainate 2 (GluK2) antagonist [91]. 
 
In summary, although CA3 pyramidal cells appear to show the highest expression of KAR 
subunits (GluK2, GluK4 and GluK5), in agreement with the high density of H3-kainate binding 
sites, expression of KARs is far from being restricted to CA3 pyramidal cells [58]. KAR 
subunits are also expressed in CA1 pyramidal cells (GluK2 and GluK5) and in granule cells of 
the DG (GluK2, GluK3, GluK4 and GluK5) as well as in interneurons of the striatum orients 
and striatum radiatum (GluK1, GluK2 and in part GluK3). There is no evidence thus far for 





QUIN is a component of a major metabolic pathway of tryptophan degradation and can 
modulate some local events in the central nervous system [92]. However, under pathological 
conditions, it is capable of inducing a potent neurotoxic pattern by different mechanisms [93, 
94]. Under normal conditions, QUIN is produced as a downstream transient metabolite of 
tryptophan involved in adenine dinucleotide (NAD+) synthesis, since the kynurenine pathway 
typically catalyzes L-tryptophan into NAD+. In mammals, the majority of tryptophan comes 
from dietary intake, and is metabolized by the kynurenine pathway [93]. This metabolite is 
normally present in nano-molar concentrations in human and rat brains [95] and in nano- to 
micro-molar concentrations in cerebrospinal fluid [96]. 
 
However, under inflammatory conditions, the kynurenine pathway is stimulated by cytokines, 
particularly by interferon-γ (IFN-γ). In macrophages the exposure of corticostriatal structures to 
sub-micro-molar concentrations of QUIN has been shown to induce neuronal cell death through 
an excitotoxic mechanism [94], suggesting that this toxin can trigger multiple toxic cascades 
even at low concentrations. Moreover, excitotoxicity induced by QUIN has also been related to 
its ability to increase reactive oxygen species (ROS) / reactive nitrogen species (RNS) formation 
and further oxidative damage [92]. Other studies report that the intrastriatal infusion of QUIN 
into rodents stimulates lipid peroxidation in this region within 2 hours post lesion [97], and 
these findings have been correlated with increased extracellular levels of hydroxyl radical in the 
striatum [98]. As a result of these and other findings, there is a hypothesis that at least a fraction 
of the oxidative and cell damage induced by QUIN could correspond with components that are 
independent of NMDAR overactivation [98, 99]. QUIN not only induces damage to neurons, 
but also to glial cells. This discovery presents a new perspective on the toxic properties of this 
agent, and highlights the importance of designing therapeutic alternatives for neurological 
disorders involving glial cells [92]. 
 
A recent study has shown that all currently known NMDAR subunits (particularly NR1 and 
NR2A) are expressed in primary astrocytes, albeit at different levels [100]. Calcium influx 
studies have shown that QUIN activates astrocytic NMDARs, which stimulate Ca2+ influx into 
the cell. This results in dysfunction and death of astrocytes. The NMDAR ion channel blockers 
MK801 and memantine attenuate QUIN-mediated cell excitotoxicity. This suggests that the 
mechanism of QUIN gliotoxicity is at least partially mediated by excessive stimulation of 
NMDARs and the mechanism of action of QUIN on astrocytes is likely to be mediated by 
NMDARs. [101]. 
 
The molecular effects of receptors such as NMDA, KA and QUIN in the nerve cells have been 
studied predominantly in the ionotropic glutamate receptor of NMDA, because it allow that 
extracellular calcium moves down a great concentration gradient into cell and also trigger the 
release of calcium from intracellular cytoplasmic compartment. Through potent neurotoxic 
pattern by different mechanisms QUIN activates astrocytic NMDARs, which stimulate calcium 
influx into the cell, as well as QUIN-mediated cell excitotoxicity. Moreover, KA will help in 
brain inflammation, and microglia- astrocytic cell activation, and hippocampal 
neurodegeneration. 
 
2. Role of the use of inhaled anesthetics in protection against or induction of 
cytotoxicity in cells of the nervous system 
 
Isoflurane and sevoflurane are halogenated ethers used for general inhalational anesthesia. 
These volatile anesthetics reduce pain sensitivity and relax muscles. The differing effects of 
both anesthetics on the immature and mature nervous system have been investigated in recent 
years using in vitro Table 1 and in vivo murine models Table 2. The dates indicate that 
isoflurane and sevoflurane can inhibit NMDA receptor responses; these results suggest that both 
anesthetics might also be able to reduce or increase cytotoxic effects produced by excessive 
NMDA receptor stimulation, especially in the developing nervous system [102-106] 
 
In the nervous system of the developing rat, the deleterious effects of volatile anesthetics have 
demonstrated their greatest potential for harm between PD 0 - PD 14 [29, 30, 107-109] Studies 
have determined the presence of apoptosis in the developing nervous system, as measured by 
expression of activated caspase-3 (CASP-3) and increases induced by the expression in proteins 
of cleaved CASP-3, for both isoflurane and sevoflurane [29, 30, 108, 109]. 
 
This increased expression has been observed in the neocortex [109, 110], thalamus [109], 
hippocampal dentate gyrus, CA1 and CA3 [29, 30, 109, 111]. among other brain regions [108], 
as much as 24 hours after the last inhalation [30]. 
 
It has also been observed that isoflurane increased other neurodegenerative biomarkers such as 
S100β in the blood, poly-(ADP-ribose) polymerase, protein levels of glyceraldehyde-3- 
phosphate dehydrogenase, beta-site amyloid beta-precursor protein-cleaving enzyme, and the 
cell cycle regulatory proteins on CDK4 and cyclin D1 [108]. Other markers of degeneration 
have been found, including necrosis (as measured by calpain activation, and the fodrin 
breakdown product FBDP), DNA strand breaks (TUNEL), autophagy (LC3), and independent 
(AIF) apoptosis [29, 30] 
 
Cytotoxic effects of inhaled anesthetic in neonatal rats are further associated with reduced 
expression of neural nitric oxide synthases (nNOS), which may participate in neuronal apoptosis 
[111], and induction of apoptosis regulator (Bax) activation without significant cell death. This 
suggests that Bax activation may lead to destabilized mitochondria, in turn promoting cell 
vulnerability to insult, and eventual cell death [103, 112]. 
 
Moreover, maternal intrauterine exposure to anesthetic has also been shown to have harmful 
effects on the developing nervous system, with both isoflurane and sevoflurane inducing 
morphological and molecular changes [103, 113]. It has been identified that exposure to 
isoflurane in embryogenic cells triggers such changes as crista mitochondriales impairment, 
vacuolar degeneration, dilation of rough endoplasmic reticulum in irregular caryomorphism, 
and the appearance of apoptotic bodies in the cytoplasm [103]. Sevoflurane (1 minimal alveolar 
concentration (MAC), 2% for 12 h) induced cytotoxicity in primary rat cortical neurons, which was 
also associated with a high and fast elevation of peak Changes of calcium concentration in 
cytosolic space (Ca2+c) [113]. Isoflurane, but not desflurane, induces opening of mitochondrial 
permeability transition pore (mPTP), increase in levels of reactive oxygen species (ROS), 
reduction in levels of mitochondrial membrane potential and adenosine-5′-triphosphate (ATP), 
activation of CASP-3, in hippocampus neurons mouse and mice [114]. 
 
On the other hand, the exposure of gestating but not pregestation rats to sevoflurane induced 
extensive apoptotic neurodegeneration in the hippocampus of offspring at PD 0, PD 7, and PD 
14, accompanied by altered expression of CASP-3, GAP-43, nNOS, NMDAR1, and 
NMDAR2A, along with NMDAR2B upregulation of PKCα and p-JNK and downregulation of 
p-ERK and FOS protein levels [115]. 
 
In the nervous system of adult rats, isoflurane exposure for 1 MAC for 12 hours induced 
cytoxicity increased IP3R gene expression, and inhibition of IP3R activity did not completely 
block isoflurane-induced upregulation of IP3R mRNA expression, which was also associated 
with greater and faster elevation of peak (Ca2+). Sevoflurane and desflurane at equivalent 
exposure to isoflurane did not induce similar cytotoxicity or elevation of peak (Ca2+) [104, 113] 
 
In conclusion isoflurane and sevoflurane induce cytotoxicity in the nervous system, which has 
significant adverse effects on neonatal and postnatal stage. In the adult effects nervous system 
result in increased vulnerability to cell damage. The variety of mechanisms explaining this 
toxicity is related to overstimulation of NMDA, CASP-3 increases (induced expression levels of 
protein cleaved CASP-3) and neuronal apoptosis by reduction of nNOS expression and 
activation Bax induction. These findings occur during exposure to even MAC for 12 hours.  
 
3. The use of inhaled anesthetics in protecting or inducing cytotoxicity in glial cells 
 
 
The effects on glial cells, the inhaled anesthetic isoflurane especially inhibit the induction of 
lipopolysaccharide (LPS) increases proinflammatory cytokines IL -1β and affects participation 
HPA axis hypothalamic-pituitary-adrenal stress response in specifically on microglia [110]. 
Prolonged exposure to high concentrations of isoflurane induces significant cell damage, 
inhibits cell proliferation and promoted glial cell fate [113]. 
 
With respect to sevoflurane anesthetic, recent studies on the toxic effect of compound A (a 
product of degradation of sevoflurane produced by its interaction with absorbent carbon 
dioxide) it has been identified that cell degeneration progressed over time resulting in the loss of 
all viable cells. Even short exposures resulted in the massive cell death indicating that the 
compound A is a potent toxin for glial cells in vitro. A plausible mechanism for this toxicity 
involves the depletion of intracellular glutathione resulting in oxidative stress. 
 
In in vitro experiments, volatile anesthetics cause cell death in a population of glial cells 
induced by oxidative stress because these anesthetics act on iron serving as a promoter for 
protection against the toxicity and thus reduce indirect oxidative stress intracellular caused by 
this challenge [103]. 
In brief, the effects of inhaled anesthetics on the population of glial cells showed cell damage 
possibly by alterations in the cell membrane; channels of affected joints of the membrane, in the 
induction of lipopolysaccharide and alteration of the input and output mechanisms of substances 
such as glutathione. As indicated there is a greater inflammatory response and generation mechanisms 
of oxidative stress are responsible for the cell death and decreased the rate of proliferation of glial cells. 




In conclusion, toxicities in chemical injury of the central nervous system can be an 
inflammatory response mediated by high densities of microglia and astrocytes, high levels of 
proinflammatory cytokines, and caspase activation. Studies with rodents are essential to 
understanding the effect of the use of inhaled anesthetics with excitotoxic lesions in different 
developmental stages, including newborns, juveniles and adults. Understanding the mechanisms 
of regulation of cell death during development can potentially provide tools to promote 
neuroprotection and eventually achieve the repair of the nervous system in pathological 
conditions. Also certain substances, such as QUIN, not only induce damage to neurons, but also 
to glial cells. These properties of the agents used in excitotoxicity should be investigated with 
further research ranging from experimental model in vivo and in vitro, to therapeutic substitutes 
for neurological disorders involving glial cells. 
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